Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS) from a sell rating to a hold rating in a report released on Monday morning.

A number of other research firms also recently issued reports on IONS. BMO Capital Markets downgraded shares of Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $67.00 to $60.00 in a research note on Friday, August 2nd. Needham & Company LLC restated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, August 2nd. JPMorgan Chase & Co. increased their price objective on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Bank of America boosted their target price on shares of Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, TD Cowen increased their price target on shares of Ionis Pharmaceuticals from $54.00 to $59.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.00.

Ionis Pharmaceuticals Trading Down 0.8 %

Shares of IONS stock opened at $38.44 on Monday. The company has a quick ratio of 7.51, a current ratio of 7.61 and a debt-to-equity ratio of 4.67. The stock has a fifty day moving average of $41.61 and a 200 day moving average of $43.02. Ionis Pharmaceuticals has a 52 week low of $35.95 and a 52 week high of $54.44.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at about $29,000. GAMMA Investing LLC raised its position in Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after acquiring an additional 303 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth $37,000. Mather Group LLC. raised its holdings in Ionis Pharmaceuticals by 35.8% in the 2nd quarter. Mather Group LLC. now owns 911 shares of the company’s stock worth $39,000 after purchasing an additional 240 shares during the period. Finally, Capital Performance Advisors LLP bought a new position in Ionis Pharmaceuticals in the 3rd quarter worth $40,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.